oncotomskСибирский онкологический журналSiberian journal of oncology1814-48612312-3168Tomsk National Research Medical Сепtеr of the Russian Academy of Sciences10.21294/1814-4861-2017-16-6-86-92oncotomsk-645Research ArticleОБЗОРЫREVIEWSРОЛЬ ПРОЦЕССОВ АУТОФАГИИ И АНГИОГЕНЕЗА ПРИ КОЛОРЕКТАЛЬНОМ РАКЕTHE ROLE OF AUTOPHAGY AND ANGIOGENESIS IN COLORECTAL CANCERРачковскийК. В.RachkovskyK. V.

аспирант кафедры патологической анатомии

SPIN-код: 6814-7094

Postgraduate, Department of Pathological Anatomy and Cytology

SPIN-code: 6814-7094

kirillvr@yandex.ruВторушинС. В.VtorushinS. V.

доктор медицинских наук, доцент, профессор кафедры патологической анатомии, Сибирский государственный медицинский университет; старший научный сотрудник отделения патологической анатомии и цитологии, Научно-исследовательский институт онкологии, Томский национальный исследовательский медицинский центр Российской академии наук

SPIN-код: 2442-4720

MD, DSc, Professor, Pathological Anatomy Department, Siberian State Medical University; Senior Researcher of the Department of Pathological Anatomy and Cytology of Cancer Research Institute, Tomsk National Research Medical Center of the Russian Academy of Medical Sciences 

SPIN-code: 2442-4720

wtorushin@rambler.ruСтепановИ. В.StepanovI. V.

кандидат медицинских наук, доцент кафедры патологической анатомии

SPIN-код: 5930-3160.

MD, PhD, Assistent Professor, Pathological Anatomy Department

SPIN-code: 5930-3160.

 

ivanstepanov@sibmail.comНаумовС. С.NaumovS. S.

студент лечебного факультета

student

serg.nau2011@gmail.comЗавьяловаМ. В.ZavyalovaM. V.

доктор медицинских наук, профессор, заведующая кафедрой патологической анатомии, Сибирский государственный медицинский университет; ведущий научный сотрудник отделения патологической анатомии и цитологии, Научно-исследовательский институт онкологии, Томский национальный исследовательский медицинский центр Российской академии наук

SPIN-код: 1229-0323.

MD, DSc, Professor, Head of Pathological Anatomy Department, Siberian State Medical University; Senior Researcher of the Department of Pathological Anatomy and Cytology, Tomsk National Research Medical Center of the Russian Academy of Medical Sciences 

SPIN-code: 1229-0323

zavyalovamv@mail.ruАфанасьевС. Г.AfanasyevS. G.

доктор медицинских наук, профессор, главный научный сотрудник торако-абдоминального отделения

SPIN-код: 9206-3037

MD, DSc, Professor, Leading Researcher, Thoracic and Abdominal Department, Cancer Research Institute, Tomsk National Research Medical Center of the Russian Academy of Medical Science

SPIN-code: 9206-3037

Afanasievsg@oncology.tomsk.ruФГБОУ ВО «Сибирский государственный медицинский университет», г. ТомскРоссияSiberian State Medical University, TomskRussian FederationФГБОУ ВО «Сибирский государственный медицинский университет», г. Томск; Научно-исследовательский институт онкологии, Томский национальный исследовательский медицинский центр Российской академии наук, г. ТомскРоссияSiberian State Medical University, Tomsk; Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, TomskRussian FederationНаучно-исследовательский институт онкологии, Томский национальный исследовательский медицинский центр Российской академии наук, г. ТомскРоссияCancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, TomskRussian Federation2017241220171668692Copyright © Рачковский К.В., Вторушин С.В., Степанов И.В., Наумов С.С., Завьялова М.В., Афанасьев С.Г., 20172017Рачковский К.В., Вторушин С.В., Степанов И.В., Наумов С.С., Завьялова М.В., Афанасьев С.Г.Rachkovsky K.V., Vtorushin S.V., Stepanov I.V., Naumov S.S., Zavyalova M.V., Afanasyev S.G.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.siboncoj.ru/jour/article/view/645

Цель исследования – обобщение имеющихся данных о роли аутофагии и ангиогенеза в развитии, прогрессировании и оценке прогноза колоректального рака. Материал и методы. Поиск соответствующих источников производился в системах Medline, Cochrane Library, Elibrary. Из 340 найденных исследований 48 были использованы для написания систематического обзора. Результаты. На данный момент существует многообразие прогностических маркеров, используемых при изучении патогенеза, диагностике и лечении колоректального рака. В обзоре рассмотрены молекулярные механизмы участия различных белков аутофагии и ангиогенеза в патогенезе и прогрессировании коло- ректального рака, представлено потенциальное значение использования их в клинической практике. Заключение. Многие из существующих маркеров могут быть использованы при оценке не только прогноза, но и чувствительности к химиотерапии. Однако противоречивые результаты исследований в отношении некоторых белков требуют дальнейшего изучения, их валидации с последующим внедрением в практику.

 

The purpose of the study was a review of available data on the role of autophagy and angiogenesis in the development, progression and prognosis of colorectal cancer. Material and methods. Databases searched were Medline, Cochrane Library and Elibrary. Of 340 studies, 48 were used to write a systematic review. Results. To date, there is a variety of prognostic markers used in the study of pathogenesis, diagnosis and treatment of colorectal cancer. The review describes the molecular mechanisms of the participation of various proteins of autophagy and angiogenesis in the pathogenesis and progression of colorectal cancer, and the potential importance of their use in clinical practice is presented. Conclusion. Many of the existing markers can be used not only in assessing the prognosis, but also sensitivity to chemotherapy. However, the contradictory results of studies with respect to certain proteins require further study, validation, and subsequent introduction into practice.

 

колоректальный ракаутофагияангиогенезфакторы прогнозаcolorectal cancerautophagyangiogenesisprognostic factorsReferencesЦиммерман Я.С. Колоректальный рак: современное состояние проблемы. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2012; 4: 5–16.Tsimmerman Ya.S. Colorectal cancer. Russian Journal of Gastroenterology, Hepatology and Coloproctology. 2012; 4: 5–16. [in Russian]Давыдов М.И., Аксель Е.М. Статистика злокачественных новообразований 2014 г. Евразийский онкологический журнал. 2016; 4 (4): 692–879.Davydov М.I., Aksel Е.М. Statistics of malignant tumors in 2014. Eurasian Journal of Oncology. 2016; 4 (4): 692–879. [in Russian]Каприн А.Д., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2015 году (заболеваемость и смертность). М., 2017. 250 с.Kaprin А.D., Starinsky V.V., Petrova G.V. Cancer incidence and mortality in Russia in 2015. Мoscow: 2017, 250 p. [in Russian]Имянитов Е.Н. Клинико-молекулярные аспекты колоректального рака: этиопатогенез, профилактика, индивидуализация лечения. Практическая онкология. 2005; 6 (2): 65–70.Imyanitov Е.N. Clonical and molecular aspects of colorectal cancer: pathogenesis, prevention and personalized treatment. Practical Oncology. 2005; 6 (2): 65–70. [in Russian]Gil J., Pesz K.A., Sasiadek M.M. May autophagy be a novel bio-marker andantitumor target in colorectal cancer? Biomarkers in Medicine. 2016; 10 (10): 1081–1094. doi: 10.2217/bmm-2016-0083.Gil J., Pesz K.A., Sasiadek M.M. May autophagy be a novel bio-marker andantitumor target in colorectal cancer? Biomarkers in Medicine. 2016; 10 (10): 1081–1094. doi: 10.2217/bmm-2016-0083.Rabinowitz J.D., White E. Autophagy and metabolism. Science. 2010; 330: 13441348. doi: 10.1126/science.1193497.Rabinowitz J.D., White E. Autophagy and metabolism. Science. 2010; 330: 13441348. doi: 10.1126/science.1193497.Degenhardt K., Mathew R., Beaudoin B., Bray K., Anderson D., Chen G., Mukherjee C., Shi Y., Gélinas C., Fan Y., Nelson D.A., Jin S., White E. Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis. Cancer Cell. 2006 Jul; 10 (1): 51–64.Degenhardt K., Mathew R., Beaudoin B., Bray K., Anderson D., Chen G., Mukherjee C., Shi Y., Gélinas C., Fan Y., Nelson D.A., Jin S., White E. Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis. Cancer Cell. 2006 Jul; 10 (1): 51–64.Burada F., Nicoli E.R., Ciurea M.E., Uscatu D.C., Ioana M., Gheonea D.I. Autophagy in colorectal cancer: An important switch from physiology to pathology. World J Gastrointest Oncol. 2015 Nov 15; 7 (11): 271–84. doi: 10.4251/wjgo.v7.i11.271.Burada F., Nicoli E.R., Ciurea M.E., Uscatu D.C., Ioana M., Gheonea D.I. Autophagy in colorectal cancer: An important switch from physiology to pathology. World J Gastrointest Oncol. 2015 Nov 15; 7 (11): 271–84. doi: 10.4251/wjgo.v7.i11.271.Dunn W.A.Jr. Autophagy and related mechanisms of lysosome-mediated proteindegradation. Trends Cell Biol. 1994 Apr; 4 (4): 139–43.Dunn W.A.Jr. Autophagy and related mechanisms of lysosome-mediated protein degradation. Trends Cell Biol. 1994 Apr; 4 (4): 139–43.Liu L., Meng T., Wang Q.S., Jin H.Z., Sun Z.Q., Jin B., Fang F., Wang H.J. Association of Beclin-1 and microRNA-30a expression with the severity and treatment response of colorectal cancer. Genet Mol Res. 2016 Apr 7; 15 (2). doi: 10.4238/gmr.15027704.Liu L., Meng T., Wang Q.S., Jin H.Z., Sun Z.Q., Jin B., Fang F., Wang H.J. Association of Beclin-1 and microRNA-30a expression with the severity and treatment response of colorectal cancer. Genet Mol Res. 2016 Apr 7; 15 (2). doi: 10.4238/gmr.15027704.Jiang Z.F., Shao L.J., Wang W.M., Yan X.B., Liu R.Y. Decreased expression of Beclin-1 and LC3 in human lung cancer. Mol Biol Rep. 2012 Jan; 39 (1): 259–67. doi: 10.1007/s11033-011-0734-1.Jiang Z.F., Shao L.J., Wang W.M., Yan X.B., Liu R.Y. Decreased expression of Beclin-1 and LC3 in human lung cancer. Mol Biol Rep. 2012 Jan; 39 (1): 259–67. doi: 10.1007/s11033-011-0734-1.Schmitz K.J., Ademi C., Bertram S., Schmid K.W., Baba H.A. Prognostic relevance of autophagy-related markers LC3, p62/sequesto-some 1, Beclin-1 and ULK1 in colorectal cancer patients with respect to KRAS mutational status. World J Surg Oncol. 2016 Jul 22; 14 (1): 189. doi: 10.1186/s12957-016-0946-x.Schmitz K.J., Ademi C., Bertram S., Schmid K.W., Baba H.A. Prognostic relevance of autophagy-related markers LC3, p62/sequesto-some 1, Beclin-1 and ULK1 in colorectal cancer patients with respect to KRAS mutational status. World J Surg Oncol. 2016 Jul 22; 14 (1): 189. doi: 10.1186/s12957-016-0946-x.Chen Z., Li Y., Zhang C., Yi H., Wu C., Wang J., Liu Y., Tan J., Wen J. Downregulation of Beclin 1 and impairment of autophagy in a small population of colorectal cancer. Dig Dis Sci. 2013; 58: 2887–2894. doi: 10.1007/s10620-013-2732-8.Chen Z., Li Y., Zhang C., Yi H., Wu C., Wang J., Liu Y., Tan J., Wen J. Downregulation of Beclin 1 and impairment of autophagy in a small population of colorectal cancer. Dig Dis Sci. 2013; 58: 2887–2894. doi: 10.1007/s10620-013-2732-8.Levine B., Kroemer G. Autophagy in the pathogenesis of disease. Cell. 2008 Jan 11; 132 (1): 27–42. doi: 10.1016/j.cell.2007.12.018.Levine B., Kroemer G. Autophagy in the pathogenesis of disease. Cell. 2008 Jan 11; 132 (1): 27–42. doi: 10.1016/j.cell.2007.12.018.Laddha S.V., Ganesan S., Chan C.S., White E. Mutational landscape of the essential autophagy gene BECN1 in human cancers. Mol Cancer Res. 2014; 12: 485–490. doi: 10.1158/1541-7786.MCR-13-0614.Laddha S.V., Ganesan S., Chan C.S., White E. Mutational landscape of the essential autophagy gene BECN1 in human cancers. Mol Cancer Res. 2014; 12: 485–490. doi: 10.1158/1541-7786.MCR-13-0614.Sahni S., Merlot A.M., Krishan S., Jansson P.J., Richardson D.R. Gene of the month: BECN1. J Clin Pathol. 2014 Aug; 67 (8): 656–60. doi: 10.1136/jclinpath-2014-202356.Sahni S., Merlot A.M., Krishan S., Jansson P.J., Richardson D.R. Gene of the month: BECN1. J Clin Pathol. 2014 Aug; 67 (8): 656–60. doi: 10.1136/jclinpath-2014-202356.Koukourakis M.I., Giatromanolaki A., Sivridis E., Pitiakoudis M., Gatter K.C., Harris A.L. Beclin 1 over- and underexpression in colorectal cancer: distinct patterns relate to prognosis and tumour hypoxia. Br J Cancer. 2010; 103: 1209–1214. doi: 10.1038/sj.bjc.6605904.Koukourakis M.I., Giatromanolaki A., Sivridis E., Pitiakoudis M., Gatter K.C., Harris A.L. Beclin 1 over- and underexpression in colorectal cancer: distinct patterns relate to prognosis and tumour hypoxia. Br J Cancer. 2010; 103: 1209–1214. doi: 10.1038/sj.bjc.6605904.Wu S., Sun C., Tian D., Li Y., Gao X., He S., Li T. Expression and clinical significances of Beclin1, LC3 and mTOR in colorectal cancer. Int J Clin Exp Pathol. 2015; 8 (4): 3882–91. eCollection 2015.Wu S., Sun C., Tian D., Li Y., Gao X., He S., Li T. Expression and clinical significances of Beclin1, LC3 and mTOR in colorectal cancer. Int J Clin Exp Pathol. 2015; 8 (4): 3882–91. eCollection 2015.Kundu M., Wang B. Canonical and noncanonical functions of ULK/Atg1. Curr Opin Cell Biol. 2017 Apr; 45: 47–54. doi: 10.1016/j. ceb.2017.02.011.Kundu M., Wang B. Canonical and noncanonical functions of ULK/Atg1. Curr Opin Cell Biol. 2017 Apr; 45: 47–54. doi: 10.1016/j. ceb.2017.02.011.Amaravadi R., Kimmelman A.C., White E. Recent insights into the function of autophagy in cancer. Genes Dev. 2016 Sep 1; 30 (17): 1913–30. doi: 10.1101/gad.287524.116.Amaravadi R., Kimmelman A.C., White E. Recent insights into the function of autophagy in cancer. Genes Dev. 2016 Sep 1; 30 (17): 1913–30. doi: 10.1101/gad.287524.116.Jiang S., Li Y., Zhu Y.H., Wu X.Q., Tang J., Li Z., Feng G.K., Deng R., Li D.D., Luo R.Z., Zhang M.F., Qin W., Wang X., Jia W.H., Zhu X.F. Intensive expression of UNC-51-like kinase 1 is a novel biomarker of poor prognosis in patients with esophageal squamous cell carcinoma. Cancer Sci. 2011 Aug; 102 (8): 1568–75. doi: 10.1111/j.1349-7006.2011.01964.x.Jiang S., Li Y., Zhu Y.H., Wu X.Q., Tang J., Li Z., Feng G.K., Deng R., Li D.D., Luo R.Z., Zhang M.F., Qin W., Wang X., Jia W.H., Zhu X.F. Intensive expression of UNC-51-like kinase 1 is a novel biomarker of poor prognosis in patients with esophageal squamous cell carcinoma. Cancer Sci. 2011 Aug; 102 (8): 1568–75. doi: 10.1111/j.1349-7006.2011.01964.x.Pike L.R., Singleton D.C., Buffa F., Abramczyk O., Phadwal K., Li J.L., Simon A.K., Murray J.T., Harris A.L. Transcriptional up-regulation of ULK1 by ATF4 contributes to cancer cell survival. Biochem J. 2013; 449: 389–400. doi: 10.1042/BJ20120972.Pike L.R., Singleton D.C., Buffa F., Abramczyk O., Phadwal K., Li J.L., Simon A.K., Murray J.T., Harris A.L. Transcriptional up-regulation of ULK1 by ATF4 contributes to cancer cell survival. Biochem J. 2013; 449: 389–400. doi: 10.1042/BJ20120972.Tang J., Deng R., Luo R.Z., Shen G.P., Cai M.Y., Du Z.M., Jiang S., Yang M.T., Fu J.H., Zhu X.F. Low expression of ULK1 is associated with operable breast cancer progression and is an adverse prognostic marker of survival for patients. Breast Cancer Res Treat. 2012; 134: 549–60. doi: 10.1007/s10549-012-2080-y.Tang J., Deng R., Luo R.Z., Shen G.P., Cai M.Y., Du Z.M., Jiang S., Yang M.T., Fu J.H., Zhu X.F. Low expression of ULK1 is associated with operable breast cancer progression and is an adverse prognostic marker of survival for patients. Breast Cancer Res Treat. 2012; 134: 549–60. doi: 10.1007/s10549-012-2080-y.Gao C., Cao W., Bao L., Zuo W., Xie G., Cai T., Fu W., Zhang J., Wu W., Zhang X., Chen Y.G. Autophagy negatively regulates Wnt signalling by promoting Dishevelled degradation. Nature Cell Biology. 2010; 12 (8): 781–90. doi: 10.1038/ncb2082.Gao C., Cao W., Bao L., Zuo W., Xie G., Cai T., Fu W., Zhang J., Wu W., Zhang X., Chen Y.G. Autophagy negatively regulates Wnt signalling by promoting Dishevelled degradation. Nature Cell Biology. 2010; 12 (8): 781–90. doi: 10.1038/ncb2082.Linares J.F., Amanchy R., Greis K., Diaz-Meco M.T., Moscat J. Phosphorylation of p62 by cdk1 controls the timely transit of cells through mitosis and tumor cell proliferation. Mol Cell Biol. 2011; 31 (1): 105–117. doi: 10.1128/mcb.00620-10.Linares J.F., Amanchy R., Greis K., Diaz-Meco M.T., Moscat J. Phosphorylation of p62 by cdk1 controls the timely transit of cells through mitosis and tumor cell proliferation. Mol Cell Biol. 2011; 31 (1): 105–117. doi: 10.1128/mcb.00620-10.Jeong W.J., Cha P.H., Choi K.Y. Strategies to overcome resistance to epidermal growth factor receptor monoclonal antibody therapy in metastatic colorectal cancer. World J Gastroenterol. 2014 Aug 7; 20 (29): 9862–71. doi: 10.3748/wjg.v20.i29.9862.Jeong W.J., Cha P.H., Choi K.Y. Strategies to overcome resistance to epidermal growth factor receptor monoclonal antibody therapy in metastatic colorectal cancer. World J Gastroenterol. 2014 Aug 7; 20 (29): 9862–71. doi: 10.3748/wjg.v20.i29.9862.Chen Z., Gao S., Wang D., Song D., Feng Y. Colorectal cancer cells are resistant to anti-EGFR monoclonal antibody through adapted autophagy. Am J Transpl Res. 2016; 8 (2): 1190–6. eCollection 2016.Chen Z., Gao S., Wang D., Song D., Feng Y. Colorectal cancer cells are resistant to anti-EGFR monoclonal antibody through adapted autophagy. Am J Transpl Res. 2016; 8 (2): 1190–6. eCollection 2016.Mei Q., Li F., Quan H., Liu Y., Xu H. Busulfan inhibits growth of human osteosarcoma through miR-200 family microRNAs in vitro and in vivo. Cancer Sci. 2014; 105: 755–762. doi: 10.1111/cas.12436.Mei Q., Li F., Quan H., Liu Y., Xu H. Busulfan inhibits growth of human osteosarcoma through miR-200 family microRNAs in vitro and in vivo. Cancer Sci. 2014; 105: 755–762. doi: 10.1111/cas.12436.Liu G., Jiang C., Li D., Wang R., Wang W. MiRNA-34a inhibits EGFR-signaling-dependent MMP7 activation in gastric cancer. Tumour Biol. 2014 Oct; 35 (10): 9801–6. doi: 10.1007/s13277-014-2273-6.Liu G., Jiang C., Li D., Wang R., Wang W. MiRNA-34a inhibits EGFR-signaling-dependent MMP7 activation in gastric cancer. Tumour Biol. 2014 Oct; 35 (10): 9801–6. doi: 10.1007/s13277-014-2273-6.Zhu H., Wu H., Liu X., Li B., Chen Y., Ren X., Liu C.G., Yang J.M. Regulation of autophagy by a beclin 1-targeted microRNA, miR-30a, in cancer cells. Autophagy. 2009; 5 (6): 816–823.Zhu H., Wu H., Liu X., Li B., Chen Y., Ren X., Liu C.G., Yang J.M. Regulation of autophagy by a beclin 1-targeted microRNA, miR-30a, in cancer cells. Autophagy. 2009; 5 (6): 816–823.Minder P., Zajac E., Quigley J.P., Deryugina E.I. EGFR Regulates the Development and Microarchitecture of Intratumoral Angiogenic Vasculature Capable of Sustaining Cancer Cell Intravasation. Neoplasia. 2015; 17 (8): 634–49 doi: 10.1016/j.neo.2015.08.002.Minder P., Zajac E., Quigley J.P., Deryugina E.I. EGFR Regulates the Development and Microarchitecture of Intratumoral Angiogenic Vasculature Capable of Sustaining Cancer Cell Intravasation. Neoplasia. 2015; 17 (8): 634–49 doi: 10.1016/j.neo.2015.08.002.Mousa L., Salem M.E., Mikhail S. Biomarkers of Angiogenesis in Colorectal Cancer. Biomarkers in cancer. 2015; 7 (suppl 1): 13–19. doi:10.4137/BIC.S25250.Mousa L., Salem M.E., Mikhail S. Biomarkers of Angiogenesis in Colorectal Cancer. Biomarkers in cancer. 2015; 7 (suppl 1): 13–19. doi:10.4137/BIC.S25250.Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005; 307 (5706): 58–62. doi: 10.1126/science.1104819.Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005; 307 (5706): 58–62. doi: 10.1126/science.1104819.Brown L.F., Berse B., Jackman R.W., Tognazzi K., Manseau E.J., Senger D.R., Dvorak H.F. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Res. 1993; 53(19): 4727–4735.Brown L.F., Berse B., Jackman R.W., Tognazzi K., Manseau E.J., Senger D.R., Dvorak H.F. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Res. 1993; 53(19): 4727–4735.Jantus-Lewintre E., Sanmartín E., Sirera R., Blasco A., Sanchez J.J., Taron M., Rosell R., Camps C. Combined VEGF-A and VEGFR-2 concentrations in plasma: diagnostic and prognostic implications in patients with advanced NSCLC. Lung Cancer. 2011 Nov; 74 (2): 326–31. doi: 10.1016/j.lungcan.2011.02.016.Jantus-Lewintre E., Sanmartín E., Sirera R., Blasco A., Sanchez J.J., Taron M., Rosell R., Camps C. Combined VEGF-A and VEGFR-2 concentrations in plasma: diagnostic and prognostic implications in patients with advanced NSCLC. Lung Cancer. 2011 Nov; 74 (2): 326–31. doi: 10.1016/j.lungcan.2011.02.016.Zhang S.D., McCrudden C.M., Meng C., Lin Y., Kwok H.F. The significance of combining VEGFA, FLT1, and KDR expressions in colon cancer patient prognosis and predicting response to bevacizumab. Onco Targets Ther. 2015; 8: 835–843. doi: 10.2147/OTT.S80518.Zhang S.D., McCrudden C.M., Meng C., Lin Y., Kwok H.F. The significance of combining VEGFA, FLT1, and KDR expressions in colon cancer patient prognosis and predicting response to bevacizumab. Onco Targets Ther. 2015; 8: 835–843. doi: 10.2147/OTT.S80518.Stiegelbauer V., Perakis S., Deutsch A., Ling H., Gerger A., Pichler M. MicroRNAs as novel predictive biomarkers and therapeutic targets in colorectal cancer. World J Gastroenterol. 2014; 20 (33): 11727–11735. doi: 10.3748/wjg.v20.i33.11727.Stiegelbauer V., Perakis S., Deutsch A., Ling H., Gerger A., Pichler M. MicroRNAs as novel predictive biomarkers and therapeutic targets in colorectal cancer. World J Gastroenterol. 2014; 20 (33): 11727–11735. doi: 10.3748/wjg.v20.i33.11727.Hansen T.F., Christensen R.D., Andersen R.F., Sørensen F.B., Johnsson A., Jakobsen A. MicroRNA-126 and epidermal growth factor-like domain 7-an angiogenic couple of importance in metastatic colorectal cancer. Results from the Nordic ACT trial. Br J Cancer. 2013; 109 (5): 1243–51. doi: 10.1038/bjc.2013.448.Hansen T.F., Christensen R.D., Andersen R.F., Sørensen F.B., Johnsson A., Jakobsen A. MicroRNA-126 and epidermal growth factor-like domain 7-an angiogenic couple of importance in metastatic colorectal cancer. Results from the Nordic ACT trial. Br J Cancer. 2013; 109 (5): 1243–51. doi: 10.1038/bjc.2013.448.Pietrzyk L. Biomarkers Discovery for Colorectal Cancer: A Review on Tumor Endothelial Markers as Perspective Candidates. Disease Markers. 2016; 2016: 1–11. doi: 10.1155/2016/4912405.Pietrzyk L. Biomarkers Discovery for Colorectal Cancer: A Review on Tumor Endothelial Markers as Perspective Candidates. Disease Markers. 2016; 2016: 1–11. doi: 10.1155/2016/4912405.St Croix B., Rago C., Velculescu V., Traverso G., Romans K.E., Montgomery E., Lal A., Riggins G.J., Lengauer C., Vogelstein B., Kinzler K.W. Genes expressed in human tumor endothelium. Science. 2000; 289: 1197–1202. doi: 10.1126/science.289.5482.1197.St Croix B., Rago C., Velculescu V., Traverso G., Romans K.E., Montgomery E., Lal A., Riggins G.J., Lengauer C., Vogelstein B., Kinzler K.W. Genes expressed in human tumor endothelium. Science. 2000; 289: 1197–1202. doi: 10.1126/science.289.5482.1197.Mehran R., Nilsson M., Khajavi M., Du Z., Cascone T., Wu H.K., Cortes A., Xu L., Zurita A., Schier R., Riedel B., El-Zein R., Heymach J.V. Tumor endothelialmarkers define novel subsets of cancer-specific circulating endothelial cells associated with antitumor efficacy. Cancer Res. 2014; 74 (10): 2731–41. doi: 10.1158/0008-5472.CAN-13-2044.Mehran R., Nilsson M., Khajavi M., Du Z., Cascone T., Wu H.K., Cortes A., Xu L., Zurita A., Schier R., Riedel B., El-Zein R., Heymach J.V. Tumor endothelialmarkers define novel subsets of cancer-specific circulating endothelial cells associated with antitumor efficacy. Cancer Res. 2014; 74 (10): 2731–41. doi: 10.1158/0008-5472.CAN-13-2044.Carson-Walter E.B., Watkins D.N., Nanda A., Vogelstein B., Kinzler K.W., St Croix B. Cell surface tumor endothelial markers are conserved in mice and humans. Cancer Res. 2001; 61 (18): 6649–55.Carson-Walter E.B., Watkins D.N., Nanda A., Vogelstein B., Kinzler K.W., St Croix B. Cell surface tumor endothelial markers are conserved in mice and humans. Cancer Res. 2001; 61 (18): 6649–55.Rmali K.A., Puntis M.C.A., Jiang W.G. Prognostic values of tumor endothelial markers in patients with colorectal cancer. World J Gastroenterol. 2005 Mar 7; 11(9): 1283–6.Rmali K.A., Puntis M.C.A., Jiang W.G. Prognostic values of tumor endothelial markers in patients with colorectal cancer. World J Gastroenterol. 2005 Mar 7; 11(9): 1283–6.Tomkowicz B., Rybinski K., Foley B., Ebel W., Kline B., Routhier E., Sass P., Nicolaides N.C., Grasso L., Zhou Y. Interaction of endosialin/ TEM1 with extracellular matrix proteins mediates cell adhesion and migration. Proc Natl Acad Sci USA. 2007; 104 (46): 17965–70. doi: 10.1073/ pnas.0705647104.Tomkowicz B., Rybinski K., Foley B., Ebel W., Kline B., Routhier E., Sass P., Nicolaides N.C., Grasso L., Zhou Y. Interaction of endosialin/ TEM1 with extracellular matrix proteins mediates cell adhesion and migration. Proc Natl Acad Sci USA. 2007; 104 (46): 17965–70. doi: 10.1073/ pnas.0705647104.Davies G., Cunnick G.H., Mansel R.E., Mason M.D., Jiang W.G. Levels of expression of endothelial markers specific to tumour-associated endothelial cells and their correlation with prognosis in patients with breast cancer. Clin Exp Metastasis. 2004; 21 (1): 31–37. doi: 10.1023/ B:CLIN.0000017168.83616.d.Davies G., Cunnick G.H., Mansel R.E., Mason M.D., Jiang W.G. Levels of expression of endothelial markers specific to tumour-associated endothelial cells and their correlation with prognosis in patients with breast cancer. Clin Exp Metastasis. 2004; 21 (1): 31–37. doi: 10.1023/ B:CLIN.0000017168.83616.d.Dolznig H., Schweifer N., Puri C., Kraut N., Retting W.J., Kerjaschki D., Garin-Chesa P. Characterization of cancer stroma markers: In silico analysis of an mRNA expression database for fibroblast activation protein and endosialin. Cancer Imm. 2005; 5: 10.Dolznig H., Schweifer N., Puri C., Kraut N., Retting W.J., Kerjaschki D., Garin-Chesa P. Characterization of cancer stroma markers: In silico analysis of an mRNA expression database for fibroblast activation protein and endosialin. Cancer Imm. 2005; 5: 10.Brady J., Neal J., Sadakar N., Gasque P. Human endosialin (tumor endothelial marker 1) is abundantly expressed in highly malignant and invasive brain tumors. J Neuropathol Exp Neurol. 2004; 63 (12): 1274–1283. doi: 10.1093/jnen/63.12.1274.Brady J., Neal J., Sadakar N., Gasque P. Human endosialin (tumor endothelial marker 1) is abundantly expressed in highly malignant and invasive brain tumors. J Neuropathol Exp Neurol. 2004; 63 (12): 1274–1283. doi: 10.1093/jnen/63.12.1274.Huber M.A., Kraut N., Schweifer N., Dolznig H., Peter R.U., Schubert R.D., Scharffetter-Kochanek K., Pehamberger H., Garin-Chesa P. Expression of stromal cell markers in distinct compartments of human skin cancers. J Cutan Pathol. 2006; 33 (2): 145–155. doi:10.1111/j.0303-6987.2006.00446.x.Huber M.A., Kraut N., Schweifer N., Dolznig H., Peter R.U., Schubert R.D., Scharffetter-Kochanek K., Pehamberger H., Garin-Chesa P. Expression of stromal cell markers in distinct compartments of human skin cancers. J Cutan Pathol. 2006; 33 (2): 145–155. doi:10.1111/j.0303-6987.2006.00446.x.

The authors declare that there are no conflicts of interest present.